Abstract
Background:Baricitinib (bari) is an oral Janus kinase (JAK) 1/JAK2 selective inhibitor that has shown good efficacy in patients with RA and adequate response to conventional synthetic DMARDs in some clinical...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have